Christina Bellinger, MD
Pulmonary Disease · Winston Salem, NCNPI 1205023025
Payments from drug & device makers
Across 67 payments — averaging $475.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mirati Therapeutics, Inc.$13K
- Intuitive Surgical$10K
- Elucent Medical$6K
- Pulmonx Corporation$1K
- Cook Incorporated$750
- Galvanize Therapeutics, Inc$427
- plus $432 from 6 others
What the payments were for
- Consulting fees$4001%
- Speaking & faculty fees$7,55024%
- Travel & lodging$16,84153%
- Food & beverage$2,2897%
- Education$4,80715%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mirati Therapeutics, Inc. | 5 | $12,549 |
| Intuitive Surgical | 39 | $10,312 |
| Elucent Medical | 1 | $6,300 |
| Pulmonx Corporation | 10 | $1,117 |
| Cook Incorporated | 1 | $750 |
| Galvanize Therapeutics, Inc | 4 | $427 |
| Optellum Ltd | 1 | $150 |
| Olympus America Inc. | 2 | $117 |
| Pinnacle Biologics, Inc | 1 | $61 |
| Imbio Inc. | 1 | $57 |
| Olympus Corporation Of The Americas | 1 | $26 |
| Gilead | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$31,887 in reported general payments places this provider in the 80th percentile of 393 pulmonary disease providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $49,844 |
| Breo ElliptaFluticasone/Vilanterol | 64 | $40,460 |
| Spiriva HandihalerTiotropium Bromide | 46 | $32,675 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 19 | $16,250 |
| Arnuity ElliptaFluticasone Furoate | 44 | $13,481 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 21 | $11,338 |
| SymbicortBudesonide/Formoterol Fumarate | 34 | $9,316 |
| Spiriva RespimatTiotropium Bromide | 18 | $9,185 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 11 | $9,012 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 19 | $8,165 |
| Incruse ElliptaUmeclidinium Bromide | 20 | $7,513 |
| Ventolin HfaAlbuterol Sulfate | 55 | $3,547 |
| Wixela InhubFluticasone Propion/Salmeterol | 13 | $3,271 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 116 | $3,212 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 13 | $2,420 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Winston Salem
- Wendy MooreWinston Salem$892K
- Eugene BleeckerWinston Salem$739K
- Jill OharWinston Salem$558K
- Kapilkumar PatelWinston Salem$480K
- Chad MarionWinston Salem$265K
- Victor OrtegaWinston Salem$150K
- Andrew NamenWinston Salem$119K
- Jessica FieldWinston Salem$71K
- Daniel FilesWinston Salem$69K
- Karl ThomasWinston Salem$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.